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Abstract
Background: Statins are widely prescribed to patients with atherosclerosis. A retrospective database analysis was
used to examine the role of preoperative statin use in hospital mortality, for patients undergoing isolated coronary
artery bypass grafting (CABG.)
Methods: The study population comprised 2377 patients who had isolated CABG at Allegheny General Hospital
between 2000 and 2004. Mean age of the patients was 65 ± 11 years (range 27 to 92 years). 1594 (67%) were
male, 5% had previous open heart procedures, and 4% had emergency surgery. 1004 patients (42%) were being
treated with a statin at the time of admission. Univariate, bivariate (Chi
2, Fisher’s Exact and Student’s t-tests) and
multivariate (stepwise linear regression) analyses were used to evaluate the association of statin use with mortality
following CABG.
Results: Annual prevalence of preoperative statin use was similar over the study period and averaged 40%.
Preoperative clinical risk assessment demonstrated a 2% risk of mortality in both the statin and non-statin groups.
Operative mortality was 2.4% for all patients, 1.7% for statin users and 2.8% for non-statin users (p < 0.07). Using
multivariate analysis, lack of statin use was found to be an independent predictor of mortality in high-risk patients
(n = 245, 12.9% vs. 5.6%, p < 0.05).
Conclusions: Between 2000 and 2004 less than 50% of patients at this institution were receiving statins before
admission for isolated CABG. A retrospective analysis of this cohort provides evidence that preoperative statin use
is associated with lower operative mortality in high-risk patients.
Introduction
The use of 3-hydroxy-3-methyl-glutaryl coenzyme A
reductase inhibitors (statins) has been shown to reduce
death, myocardial infarction and stroke in patients with
elevated serum cholesterol and in those with near nor-
mal serum cholesterol levels [1]. The mechanism of this
improvement is likely multifactorial, with some benefit
attributed to lipid lowering effects and some to lipid-
independent (pleiotropic) properties. Recently, evidence
has accumulated that statins have beneficial effects on
various portions of the clinical pathway that leads to
atherosclerosis and cardiovascular events. These effects
include downregulation of the inflammatory cascade [2],
stabilization of the endothelial cell [3], attenuation of
oxidative damage [4], decreasing thrombotic risk and
possibly plaque stabilization [5]. The use of statins has
steadily increased over time, but these drugs remain
under utilized, relative to the larger population at risk
for atherosclerosis. Patients who require coronary artery
bypass grafting (CABG) represent a small segment of
the entire population of patients with coronary artery
disease. Many CABG patients have been treated with
s t a t i n sa so u t p a t i e n t sb e f o r eC A B G ,b u tas i z e a b l e
group present with no previous statin therapy. This
study was undertaken to examine the efficacy of preo-
perative statin use on in-hospital mortality after CABG
surgery.
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Data Collection
Data were retrospectively abstracted from the institu-
tion’s cardiac surgery database, which includes over 500
variables describing patient history, pre-, intra- and
post-operative data and events and selected laboratory
and functional testing results. Data from every patient
who undergoes a major cardiac procedure is recorded
on a standardized form and entered into the database
by trained database staff during the admission and
immediately following discharge. Data is collected under
a waiver of consent from the Allegheny General Institu-
tional Review Board.
AGH Clinical Risk Score
As part of surgical consultation all patients are assigned
a numerical clinical risk score (CRS) based on preopera-
tive variables, including factors such as age, left ventri-
cular function, comorbid diseases and laboratory studies.
The risk score model is validated and has been
described fully in a previous publication [6]. A recent
study has confirmed the efficacy of the Magovern CRS
in comparison to other well known risk assessment
models [7]. The CRS ranges between 0 and 20 with a
lower score predicting lower operative mortality. In this
study, high risk patients were defined as those with a
CRS of 9 or above (predicted mortality of at least 6%).
Major postoperative morbidity was defined as the occur-
rence of any of the following complications: inotrope
use for greater than 24 hours, acute myocardial infarc-
tion, cerebrovascular accident, respiratory failure, new
onset renal failure, deep sternal wound infection or reo-
peration for bleeding/tamponade.
Operative Technique
Standard anesthesia and surgical techniques were uti-
lized for all patients. Based upon preoperative beliefs
and pathology, patients were offered conventional cardi-
opulmonary bypass or when appropriate; an off pump
technique. Conventional cardiopulmonary bypass uti-
lized systemic heparinization (300 mg/kg heparin sul-
fate) to maintain an activated clotting time (ACT) >450
seconds. Off pump cardiac surgery utilized 100 mg/kg
loading dose of heparin with a goal to maintain an ACT
>300 seconds. Moderate hypothermia 34 Celsius was
used in all cardiopulmonary bypass operations and
patients were re-warmed to 36 Celsius prior to
discontinuing the cardiopulmonary bypass. Cold blood
cardioplegia was utilized for induction and maintenance.
Patient Population
The study population comprised all patients who under-
went isolated CABG surgery between January 1, 2000
and December 31, 2004. This study period was chosen
because it afforded a large, comparable cohort of
patients in both the statin and non-statin treated
groups. Patients were considered to be in the “statin”
group if they were taking statins at the time of admis-
sion or they were started during the admission prior to
surgery. No data regardingt h es p e c i f i cd r u go rd o s e
was obtained.
Statistical Analysis
Data are expressed as mean ± standard deviation (con-
tinuous variables) or incidence and percent of the rele-
vant group. The study endpoint was defined as all cause
in-hospital mortality. Bivariate analyses were performed
to examine associations between preoperative status
variables and this endpoint, using Student’st - t e s t ,
Mann-Whitney rank sums test, Chi-square analysis and
Fisher’s exact test, as appropriate for continuous and
dichotomous variables. Variables with significant (p <
0.15) bivariate evidence of association with the endpoint
were then evaluated using stepwise logistic regression to
determine which of the variables contributed to a multi-
variate prediction model for in-hospital mortality.
BMDP Statistical Software, release 7 was used to per-
form all analyses.
Results
Both the proportion of preoperative statin usage and the
predicted mortality score for coronary bypass patients
were similar over the course of the study period (Table 1).
Table 2 illustrates the prevalence of relevant pre- and
intra-operative variables in the overall population and in
the statin and no statin study groups. There was no differ-
ence in incidence of any major preoperative co-morbidity.
Mean left ventricular ejection fraction (LVEF) was 47.4 ±
13.8 in the no-statin group and 48.6 ± 13.6 in the statin
group. Distribution of LVEF values (0-19%, 20-29%, 30-
39%, 40-49%, 50% and higher) was also similar. The no-
statin group was statistically older from the statin group
(65.4 vs. 64.8, p = 0.02), however this difference has negli-
gible clinical relevance.
Table 1 Preoperative statin usage and clinical risk score in CABG patients by year of surgery
Year: 2000 2001 2002 2003 2004
Statin Usage (%) 246/647 (38%) 220/523 (42%) 204/447 (46%) 181/423 (43%) 153/337 (45%)
Mean CRS 4.6 ± 3.7 4.5 ± 3.2 4.7 ± 3.7 4.0 ± 3.0 4.5 ± 3.2
CRS: Allegheny General Hospital cardiac surgery clinical risk score.
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more likely to be receiving statin treatment, likely
r e f l e c t i n gm o r ef o c u s e dc a r d i a cc a r ef o l l o w i n gt h ep r e -
vious surgery. Surgical indices of grafts performed, and
cross-clamp and cardiopulmonary bypass times did not
differ between groups. 13.4% of patients underwent off-
pump CABG, with no difference noted between the sta-
tin and non-statin groups. There were no differences
regarding intubation time, ICU duration and hospital
stay. The results of bivariate analysis between mortality
rate and relevant preoperative variables are shown in
Table 3. Each of these variables, with the exception of
non-insulin diabetes mellitus, was used for the multi-
variate assessment. Multivariate analysis was used to
determine which variables were independently asso-
ciated with decreased mortality in the study population.
Variables with a significant independent contribution to
mortality risk are illustrated in Table 4. When consider-
ing the entire population there was no significant contri-
bution of statins to operative risk. However the absence
of statin treatment was associated with an increase in
mortality in the subset of high risk patients with an esti-
mated risk of mortality of 6% and greater.
Multivariate regression analysis was also performed
using composite postoperative major morbidity as an
endpoint. Statin usage was not shown to have a signifi-
cant impact on composite major morbidity in this lim-
ited assessment.
Discussion
Statins are one of the most effective medicines intro-
duced in the past 25 years. Nonetheless they are still
relatively under prescribed, especially in patients without
symptomatic or obvious atherosclerosis and those with-
out severe hypercholesterolemia. Recently, our knowl-
edge regarding the biology of the non-lipid lowering, or
pleiotropic effects of statins has rapidly expanded.
Simultaneously, a number of recent reports have sug-
gested a salutary effect of statins on perioperative mor-
tality for patients undergoing CABG.
Clark, et al, reported a retrospective database study
from the Medical University of South Carolina covering
3829 patients between 1996 and 2002 [8]. Only 1044/
3829 patients received preoperative therapy (28%). In a
propensity matched analysis they demonstrated signifi-
cant association between preoperative statin therapy and
lower 30 day mortality and morbidity. These findings
paralleled those of an earlier study by Pan et al from the
Texas Heart Institute [9]. This study evaluated 1563
patients who underwent CABG with CPB at a single
institution. Multivariate analysis was used to show a
50% reduction in the risk of perioperative (30 day) death
in those patients who received statins preoperatively.
The use of statins preoperatively was not associated
with a lower incidence of post-operative complications.
In a propensity matched subgroup analysis statin ther-
apy was associated with a significantly lower risk of the
composite endpoint including death and stroke (but not
death alone).
Collard, et al, showed similar results in a large inter-
national, multi-institutional study [10]. The primary
study was a longitudinal analysis of 5436 patients at 70
centers undergoing CABG. The statin study was a post-
hoc retrospective analysis using this database and
showed reduced early cardiac mortality in patients
receiving statins who underwent elective CABG (0.3%
v s .1 . 4 % ) .F u r t h e r ,t h ed i s c o n t i n u a t i o no fs t a t i n sp o s t -
operatively was associated with increased all-cause hos-
pital mortality (2.6% vs. 0.6%) compared to those who
had statin therapy maintained.
Statin use in the current study averaged 42% (range 38
- 46%) over the five-year period of 2000-2004. The rela-
tively low prevalence may represent a referral bias in
that our center is a primary angioplasty referral center.
Consequently, many patients have a new diagnosis of
coronary artery disease and the statin is not always
started before operation, especially in the urgent or
Table 2 Study Population and results of bnivariate
analysis of statin groups
All Statin No Statin
Patients 2377 1004 1373
Age (years) 65.4 ± 10.7 64.8 ± 10.9 65.8 ± 10.3
a
Off-Pump CABG 321 (13.4%) 167 (6.9%) 154 (6.4%)
CAB Grafts 2.9 ± 1.0 2.8 ± 1.0 2.9 ± 1.1
AXC (minutes) 72.4 ± 25.1 73.0 ± 25.3 71.9 ± 24.9
CPB (minutes) 103 ± 33 104 ± 33 102 ± 32
Non-elective procedure 1376 (57%) 568 (57%) 808 (59%)
Redo Procedure 125 (5.3%) 66 (6.6%) 59 (4.3%)
b
Female gender 719 (30.2%) 298 (29.7%) 421 (30.7%)
Congestive heart failure history 316 (13.3%) 133 (13.2%) 183 (13.3%)
Cardiomegaly 94 (4.0%) 41 (4.1%) 53 (3.9%)
Atrial arrhythmia history 133 (5.6%) 43 (4.3%) 87 (6.3%)
Body mass index < 25 340 (14.3%) 132 (13.1%) 208 (15.1%)
Preoperative AMI 428 (18.0%) 167 (16.6%) 261 (19.0%)
COPD 402 (16.9%) 184 (18.3%) 218 (15.9%)
Peripheral vascular disease 340 (14.3%) 144 (14.3%) 196 (14.3%)
Stroke history 144 (6.1%) 56 (5.6%) 88 (6.4%)
Renal failure 77 (3.2%) 28 (2.8%) 49 (3.6%)
Tobacco past/current 1101 (46.3%) 499 (49.7%) 602 (43.8%)
IDDM 260 (10.9%) 124 (12.4%) 136 (9.9%)
In-hospital death 56 (2.4%) 17 (1.7%) 39 (2.8%)
c
AMI: acute myocardial infarction, a: p = 0.02; b: p = 0.01; c: p =0 . 0 7 .
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CABG population demonstrated an increase in preo-
perative statin use to greater than 80%.
T h em o s ti m p o r t a n to b j e c t i v eo ft h i ss t u d yw a st o
d e t e r m i n ei ft h eu s eo fp r e o p e r a t i v es t a t i nt h e r a p yi s
associated with reduced postoperative mortality. In each
of the 5-years of the study, the mortality rate was lower
in the group of patients exposed to statins preopera-
tively (range 26 - 60%.) In total, the net effect was to
reduce mortality from 2.8% to 1.7%. The effect was seen
in all groups, but was most notable in the high risk
cohort (12.9% vs. 5.6%, p < 0.05), where the predicted
mortality was 6% and higher.
This study was not designed to explain how statins
exert their salutary effect. Nonetheless, a number of
hypotheses are generated. Our group [11] and others
[12] have recently shown that patients undergoing heart
surgery who have elevated risk based on standard preo-
perative variables (age, left ventricular dysfunction, co-
morbid disease) have evidence of ongoing inflammation
manifested by elevated levels of inflammatory mediators
such as interleukin-6 (IL-6) and C-reactive protein
(CRP). Statins have been shown to ameliorate the
inflammatory cascade in a number of models and these
properties may confer protection from the inflammatory
response induced by open heart surgery. This may
explain the more pronounced protective effect of statins
in our high risk cohort.
Statins have also been shown in clinical trials to be
associated with decreased mortality when administered
in the first 24 hours after acute myocardial infarction
[13,14]. This may be the result of their potential ability
to limit infarct size, as demonstrated in animal models
of acute infarction [15]. These properties may contribute
to the beneficial effect associated with CABG and would
help to explain the more marked effect in high risk
patients, many of whom require urgent or emergent sur-
gery in the setting of acute ischemia or infarction.
The current study, in addition to all the other studies
on preoperative statin use, is retrospective and nonran-
domized. This introduces the issue of selection bias and
other confounding variables. The statistical analysis
minimizes this possibility, but it cannot eliminate this
issue completely. Further, we do not have specific
Table 4 Preoperative variables identified as independent
predictors of in-hospital mortality following CABG
surgery
Coefficient p value
All Patients
Atrial arrhythmia history 0.84 < 0.001
Congestive heart failure history 0.87 < 0.001
Age (years) 0.06 < 0.001
Redo procedure 1.20 0.009
Preoperative AMI 0.84 0.005
Insulin dependent diabetes 0.85 0.009
Tobacco past/current 0.77 0.024
Female gender 0.56 0.066
High Risk Patients
Insulin dependent diabetes 1.10 0.070
Preoperative statin use -1.07 0.030
AMI: acute myocardial infarction.
Table 3 Results of bnivariate analysis of mortality rates associated with selected preoperative variables
Variable: Present Not Present p value
Preoperative statin 17/1004 (1.7%) 39/1373 (2.8%) 0.07
Preoperative AMI 19/428 (4.4%) 37/1949 (1.9%) 0.002
Preoperative anemia 18/437 (4.1%) 38/1940 (2.0%) 0.007
Body mass index < 25 14/340 (4.1%) 42/2037 (2.1%) 0.02
Non insulin dependent diabetes 10/500 (2.0%) 46/1877 (2.5%) 0.55
Insulin dependent diabetes 14/260 (5.4%) 42/2117 (2.0%) 0.006
Chronic obstructive pulmonary disease 16/402 (4.0%) 40/1975 (2.0%) 0.02
Stroke history 6/144 (4.2%) 50/2233 (2.2%) 0.14
Peripheral vascular disease 12/340 (3.5%) 44/2037 (2.2%) 0.12
Renal failure history 5/77 (6.5%) 51/2300 (2.2%) 0.02
Atrial arrhythmia history 14/133 (10.5%) 42/2244 (1.9%) < 0.001
Congestive heart failure history 21/316 (6.7%) 35/2061 (1.7%) < 0.001
Tobacco past/current 33/1101 (3.0%) 23/1276 (1.8%) 0.06
Female gender 25/719 (3.5%) 31/1658 (1.9%) 0.02
Cardiomegaly 8/94 (8.5%) 48/2283 (2.1%) < 0.001
Redo procedure 9/125 (7.2%) 47/2252 (2.1%) < 0.001
Survivors In-hospital death
Age (years) 65.3 ± 10.7 71.5 ± 8.9 < 0.001
AMI: acute myocardial infarction.
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or cholesterol lowering efficacy. There may be important
factors with regard to dosage and duration of therapy
that impact the benefit of statins in this patient popula-
tion that we can not identify with this study. Nonethe-
less, we have shown a consistent reduction in
perioperative mortality in patients being treated with
statins, particularly those with elevated operative risk.
While placebo controlled trials will likely not be possi-
ble, further study of the underlying mechanisms of these
effects are needed.
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